Impact of CYP3A5 and ABCB1 gene polymorphisms on fentanyl pharmacokinetics and clinical responses in cancer patients undergoing conversion to a transdermal system

Drug Metabolism and Pharmacokinetics

Volumn 27, Issue 4, 2012, Pages 414-421

  Takashina, Yoshiaki ^a   Naito, Takafumi ^a   Mino, Yasuaki ^a   Yagi, Tatsuya ^a   Ohnishi, Kazunori ^b   Kawakami, Junichi ^a  

^a Department of Hospital Pharmacy ^*  (Japan)

^b HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

ABCB1; CYP3A5; Fentanyl; Opioid switching; Pharmacokinetics

Indexed keywords

FENTANYL; MORPHINE; OXYCODONE;

ABCB1 GENE; ADULT; AGED; ARTICLE; BLOOD SAMPLING; CANCER PAIN; CANCER PATIENT; CONSTIPATION; CONTROLLED STUDY; CYP3A5 GENE; DRUG ABSORPTION; DRUG ADMINISTRATION ROUTE; DRUG BLOOD LEVEL; DRUG RESPONSE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; DYSPHAGIA; FEMALE; GENE; GENE FREQUENCY; GENE FUNCTION; GENE IDENTIFICATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HUMAN; JAPANESE; MAJOR CLINICAL STUDY; MALE; NAUSEA AND VOMITING;

EID: 84865382796     PISSN: 13474367     EISSN: 18800920     Source Type: Journal    
DOI: 10.2133/dmpk.DMPK-11-RG-134     Document Type: Article

References (34)

1. Quigley, C.: The role of opioids in cancer pain. BMJ, 331: 825-829 (2005).
2. Agarwal, S., Polydefkis, M., Block, B., Haythornthwaite, J. and Raja, S. N.: Transdermal fentanyl reduces pain and improves functional activity in neuropathic pain states. Pain Med., 8: 554-562 (2007).
3. Welsh, J., Reid, A., Graham, J., Curto, J., MacLeod, K. and OöNeill, C.: Physiciansö knowledge of transdermal fentanyl. Palliat. Med., 19: 9-16 (2005).
4. McNamara, P.: Opioid switching from morphine to transdermal fentanyl for toxicity reduction in palliative care. Palliat. Med., 16: 425-434 (2002).
5. Morita, T., Takigawa, C., Onishi, H., Tajima, T., Tani, K., Matsubara, T., Miyoshi, I., Ikenaga, M., Akechi, T. and Uchitomi, Y.: Japan Pain, Rehabilitation, Palliative Medicine, and Psycho-Oncology (PRPP. Study Group: Opioid rotation from morphine to fentanyl in delirious cancer patients: An open-Label trial. J. Pain Symptom Manage., 30: 96-103 (2005).
6. Mercadante, S. and Bruera, E.: Opioid switching: a systematic and critical review. Cancer Treat. Rev., 32: 304-315 (2006).
7. Riley, J., Ross, J. R., Rutter, D., Wells, A. U., Goller, K., du Bois, R. and Welsh, K.: No pain relief from morphine? Individual variation in sensitivity to morphine and the need to switch to an alternative opioid in cancer patients. Support. Care Cancer, 14: 56-64 (2006).
8. Mercadante, S., Ferrera, P., Villari, P., Casuccio, A., Intravaia, G. and Mangione, S.: Frequency, indications, outcomes, and predictive factors of opioid switching in an acute palliative care unit. J. Pain Symptom Manage., 37: 632-641 (2009).
9. Park, H. J., Shinn, H. K., Ryu, S. H., Lee, H. S., Park, C. S. and Kang, J. H.: Genetic polymorphisms in the ABCB1 gene and effects of fentanyl in Koreans. Clin. Pharmacol. Ther., 81: 539-546 (2007).
10. Regnard, C. and Pelham, A.: Severe respiratory depression and sedation with transdermal fentanyl: four case studies. Palliat. Med., 17: 714-716 (2003).
11. Solassol, I., Bressolle, F., Caumette, L., Garcia, F., Poujol, S., Culine, S. and Pinguet, F.: Inter-and intraindividual variabilities in pharmacokinetics of fentanyl after repeated 72-hour transdermal applications in cancer pain patients. Ther. Drug Monit., 27: 491-498 (2005).
12. Grond, S., Radbruch, L. and Lehmann, K. M.: Clinical pharmacokinetics of transdermal opioids. Clin. Pharmacokinet., 38: 59-89 (2000).
13. Labroo, R. B., Paine, M. F., Thummel, K. E. and Kharasch, E. D.: Fentanyl metabolism by human hepatic and intestinal cytochrome P4503A4: implications for interindividual variability in disposition, efficacy, and drug interactions. Drug Metab. Dispos., 25: 1072-1080 (1997).
14. Guitton, J., Buronfosse, T., Désage, M., Lepape, A., Brazier, J. L. and Beaune, P.: Possible involvement of multiple cytochrome P450S in fentanyl and sufentanyl metabolism as opposed to alfentanyl. Biochem. Pharmacol., 53: 1613-1619 (1997).
15. Kuehl, P., Zhang, J., Lin, Y., Lamba, J., Assem, M., Schuetz, J., Watkins, P. B., Daly, A., Wrighton, S. A., Hall, S. D., Maurel, P., Relling, M., Brimer, C., Yasuda, K., Venkataramanan, R., Strom, S., Thummel, K., Boguski, M. S. and Schuetz, E.: Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat. Genet., 27: 383-391 (2001).
16. Henthorn, T. K., Liu, Y., Mahapatro, M. and Ng, K. Y.: Active transport of fentanyl by the blood-brain barrier. J. Pharmacol. Exp. Ther., 289: 1084-1089 (1999).
17. Campa, D., Gioia, A., Tomei, A., Poli, P. and Barale, R.: Association of ABCB1/MDR1 and OPRM1 gene polymorphisms with morphine pain relief. Clin. Pharmacol. Ther., 83: 559-566 (2008).
18. Japanese Society for Palliative Medicine: Cancer pain management guideline. Tokyo: Japanese Society for Palliative Medicine (2000).
19. Takashina, Y., Naito, T., Mino, Y., Kagawa, Y. and Kawakami, J.: Validated LC coupled to ESI-MS/MS analysis for fentanyl in human plasma and UV analysis in applied reservoir transdermal patches using a simple and rapid procedure. J. Clin. Pharm. Ther., 34: 523-529 (2009).
20. Fukuen, S., Fukuda, T., Maune, H., Ikenaga, Y., Yamamoto, I., Inaba, T. and Azuma, J.: Novel detection assay by PCR-RFLP and frequency of the CYP3A5 SNPs, CYP3A5*3 and *6, in a Japanese population. Pharmacogenetics, 12: 331-334 (2002).
21. Rosso Felipe, C., de Sandes, T. V., Sampaio, E. L., Park, S. I., Silva, H. T., Jr. and Medina Pestana, J. O.: Clinical impact of polymorphisms of transport proteins and enzymes involved in the metabolism of immunosuppressive drugs. Transplant. Proc., 41: 1441-1455 (2009).
22. Jin, M., Gock, S. B., Jannetto, P. J., Jentzen, J. M. and Wong, S. H.: Pharmacogenomics as molecular autopsy for forensic toxicology: genotyping cytochrome P450 3A4*1B and 3A5*3 for 25 fentanyl cases. J. Anal. Toxicol., 29: 590-598 (2005).
23. Lamba, J., Strom, S., Venkataramanan, R., Thummel, K. E., Lin, Y. S., Liu, W., Cheng, C., Lamba, V., Watkins, P. B. and Schuetz, E.: MDR1 genotype is associated with hepatic cytochrome P450 3A4 basal and induction phenotype. Clin. Pharmacol. Ther., 79: 325-338 (2006).
24. Lötsch, J., Geisslinger, G. and Tegeder, I.: Genetic modulation of the pharmacological treatment of pain. Pharmacol. Ther., 124: 168-184 (2009).
25. Anglicheau, D., Thervet, E., Etienne, I., Hurault De Ligny, B., Le Meur, Y., Touchard, G., Büchler, M., Laurent-Puig, P., Tregouet, D., Beaune, P., Daly, A., Legendre, C. and Marquet, P.: CYP3A5 and MDR1 genetic polymorphisms and cyclosporine pharmacokinetics after renal transplantation. Clin. Pharmacol. Ther., 75: 422-433 (2004).
26. Ross, J. R., Riley, J., Taegetmeyer, A. B., Sato, H., Gretton, S., du Bois, R. M. and Welsh, K. I.: Genetic variation and response to morphine in cancer patients: catechol-O-methyltransferase and multidrug resistance-1 gene polymorphisms are associated with central side effects. Cancer, 112: 1390-1403 (2008).
27. Lötsch, J., von Hentig, N., Freynhagen, R., Griessinger, N., Zimmermann, M., Doehring, A., Rohrbacher, M., Sittl, R. and Geisslinger, G.: Cross-sectional analysis of the influence of currently known pharmacogenetic modulators on opioid therapy in outpatient pain centers. Pharmacogenet. Genomics, 19: 429-436 (2009).
28. Coulbault, L., Beaussier, M., Verstuyft, C., Weickmans, H., Dubert, L., Trégouet, D., Descot, C., Parc, Y., Lienhart, A., Jaillon, P. and Becquemont, L.: Environmental and genetic factors associated with morphine response in the postoperative period. Clin. Pharmacol. Ther., 79: 316-324 (2006).
29. Zwisler, S. T., Enggaard, T. P., Noehr-Jensen, L., Mikkelsen, S., Verstuyft, C., Becquemont, L., Sindrup, S. H. and Brosen, K.: The antinociceptive effect and adverse drug reactions of oxycodone in human experimental pain in relation to genetic variations in the OPRM1 and ABCB1 genes. Fundam. Clin. Pharmacol., 24: 517-524 (2010).
30. Klepstad, P., Rakvåg, T. T., Kaasa, S., Holthe, M., Dale, O., Borchgrevink, P. C., Baar, C., Vikan, T., Krokan, H. E. and Skorpen, F.: The 118 AhG polymorphism in the human μ-opioid receptor gene may increase morphine requirements in patients with pain caused by malignant disease. Acta Anaesthesiol. Scand., 48: 1232-1239 (2004).
31. Chou, W. Y., Yang, L. C., Lu, H. F., Ko, J. Y., Wang, C. H., Lin, S. H., Lee, T. H., Concejero, A. and Hsu, C. J.: Association of mu-opioid receptor gene polymorphism (A118G. with variations in morphine consumption for analgesia after total knee arthroplasty. Acta Anaesthesiol. Scand., 50: 787-792 (2006).
32. Van Nimmen, N. F., Poels, K. L., Menten, J. J., Godderis, L. and Veulemans, H. A.: Fentanyl transdermal absorption linked to pharmacokinetic characteristics in patients undergoing palliative care. J. Clin. Pharmacol., 50: 667-678 (2010).
33. Solassol, I., Caumette, L., Bressolle, F., Garcia, F., Thézenas, S., Astre, C., Culine, S., Coulouma, R. and Pinguet, F.: Inter-and intra-individual variability in transdermal fentanyl absorption in cancer pain patients. Oncol. Rep., 14: 1029-1036 (2005).
34. Heiskanen, T., Mätzke, S., Haakana, S., Gergov, M., Vuori, E. and Kalso, E.: Transdermal fentanyl in cachectic cancer patients. Pain, 144: 218-222 (2009).